The long-term objectives are to define molecular mechanisms by which specific translocations lead to apparent transcriptional activation of the cellular proto-oncogenes in Burkitt's lymphoma (BL), an undifferentiated B-lymphocyte cancer of man, and other hematopoietic cancers. The mechanism of c-myc activation will be examined initially by: (1) molecular cloning and characterization of the Ramos BL c-myc alleles; (2) characterization of the c-myc transcript; and (3) transfection of molecular clones of c-myc into B-lymphoid cells to study the expression of the transferred c-myc genes. A recombinant DNA library will be constructed and phage clones containing c-myc gene will be identified by in situ hybridization screening of plaques. Cloned c-myc genes will be characterized to identify key structural differences between the normal and rearranged alleles that might be related to their functional differences. The structure of the c-myc transcripts will be examined by Northern blotting and S?1? nuclease mapping techniques. These studies will test the hypothesis that the effects of c-myc in Ramos BL is due to overexpression of a normal c-myc transcript (gene dosage model of malignancy). Finally, to detect the possible presence of a transcriptional enhancer sequence adjacent to the rearranged Ramos c-myc allele, the isolated c-myc alleles will be cloned into the shuttle vector pSV2-neo. These constructs will be transfected into NIH 3T3 cells and B-lymphoblastoid cell lines to detect differences in expression and regulation between the normal and rearranged c-myc allele responsible for enhanced expression. Transfection studies might also reveal differences in the ability of fibroblasts versus lymphoid cells to detect certain classes of activated proto-oncogenes. Although BL responds to chemotherapy, early clinical relapse after remission is often characterized by resistance to further therapy and a poor prognosis. Illumination of mechanisms of enhanced expression of c-myc in BL and its biological role in the genesis of this lymphoma might suggest whether this pathway is a potential target for experimental intervention. Results from these studies may be relevant to other proto-oncogenes structurally and functionally related to c-myc, and thus to other cancers in which aberrant expression of these genes might have a role in the genesis or maintenance of the malignant phenotype. (X)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA039186-02
Application #
3177932
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1984-06-15
Project End
1987-05-31
Budget Start
1985-06-01
Budget End
1986-05-31
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Wang, L M; Killary, A M; Fang, X E et al. (1988) Chromosome assignment of mouse insulin, colony stimulating factor 1, and low-density lipoprotein receptors. Genomics 3:172-6
Lowe, D G; Capon, D J; Delwart, E et al. (1987) Structure of the human and murine R-ras genes, novel genes closely related to ras proto-oncogenes. Cell 48:137-46
Naylor, S L; Sakaguchi, A Y; Spindel, E et al. (1987) Human gastrin-releasing peptide gene is located on chromosome 18. Somat Cell Mol Genet 13:87-91
Law, S W; Lackner, K J; Hospattankar, A V et al. (1985) Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. Proc Natl Acad Sci U S A 82:8340-4
Sakaguchi, A Y; Mohandas, T; Naylor, S L (1985) A human c-src gene resides on the proximal long arm of chromosome 20 (cen----q131). Cancer Genet Cytogenet 18:123-9
Todd, S; Yoshida, M C; Fang, X E et al. (1985) Genes for insulin I and II, parathyroid hormone, and calcitonin are on rat chromosome 1. Biochem Biophys Res Commun 131:1175-80